Home > News > Altair Nanotechnologies Licenses RenaZorb(TM)
January 31st, 2005
Altair Nanotechnologies Licenses RenaZorb(TM)
Abstract:
Altair Nanotechnologies announced today that a licensing agreement has been signed with California-based Spectrum Pharmaceuticals, giving Spectrum the exclusive worldwide rights for human therapeutic and diagnostic applications to develop, market and sell its RenaZorb™ product line. Altair's RenaZorb™ products, which target an emerging billion-dollar-plus market, are for phosphate control in patients with Chronic Kidney Disease (CKD) and hyperphosphatemia, high phosphate levels in blood, associated with End Stage Renal Disease (ESRD). These products are non-aluminum-, non-calcium-based phosphate binders, which utilize Altair's proprietary lanthanum nanomaterial technology.
Source:
marketwire
Related Links |
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||